A rare case of tirzepatide-induced liver injury
Journal of Medicine and Therapeutics · 2026 · 8 (1)
DOI: 10.15761/jmt.1000151 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicine and Therapeutics, 2026. Verfasst von Radhika Sudhir und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Tirzepatide, known commercially as Mounjaro, is a Glucagon-like peptide 1/glucose-dependent insulinotropic peptide (GIP) receptor agonist that has been recently popularised as a novel weight loss agent owing to its effects of delaying gastric emptying, increasing satiety and reducing overall food intake.The drug has been approved for use as in weight loss management by NICE within the UK and internationally.Adverse reactions from Tirzepatide use most commonly include nausea, vomiting and diarrhoea.Liver injury secondary to Mounjaro is currently poorly recognised and a literature search revealed only three previously published case reports of Tirzepatide-induced liver injury.In this case, a 42-year-old female patient presented with a four-week history of pruritus, nausea, fatigue and dark urine.There was no history of travel, allergen exposure, recreational drug use, oral contraceptive therapy or excessive alcohol intake.The patient had a three-month history of Mounjaro use, which patient had stopped a few weeks prior to her attendance at the emergency department.Serological tests found deranged liver function tests, including a serum AST of 1155 U/L and AST measuring 697U/L.An autoantibody screen and virology screen were negative.Ultrasound and MRCP both showed no abnormalities.A core biopsy of the liver showed mixed pattern of inflammation characterised by canalicular cholestasis, periportal chronic inflammation, focal interface activity and scattered lobular inflammation, consistent with drug-induced liver injury (DILI).The mechanism of hepatic injury secondary to Mounjaro is unclear.Previously published case reports have highlighted the 5 day half-life and slow metabolism of the drug, which may explain the latent onset of symptoms.Ongoing monitoring of Tirzepatide-associated adverse effects is recommended.
Zitieren
APA
Sudhir, R., & Atwan, M. (2026). A rare case of tirzepatide-induced liver injury. Journal of Medicine and Therapeutics, 8(1). https://doi.org/10.15761/jmt.1000151
Vancouver
Sudhir R, Atwan M. A rare case of tirzepatide-induced liver injury. Journal of Medicine and Therapeutics. 2026;8(1). doi:10.15761/jmt.1000151
BibTeX
@article{Sudhir2026,
author = {Sudhir, Radhika and Atwan, Manal},
title = {A rare case of tirzepatide-induced liver injury},
journal = {Journal of Medicine and Therapeutics},
year = {2026},
volume = {8},
number = {1},
doi = {10.15761/jmt.1000151}
}
EUVIMED